HealthEquity (HQY)
(Delayed Data from NSDQ)
$81.68 USD
+2.56 (3.24%)
Updated May 31, 2024 04:00 PM ET
After-Market: $82.69 +1.01 (1.24%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.68 USD
+2.56 (3.24%)
Updated May 31, 2024 04:00 PM ET
After-Market: $82.69 +1.01 (1.24%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
Zacks News
HealthEquity (HQY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
HealthEquity (HQY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Premier, Inc. (PINC) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.67% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
XpresSpa Group, Inc. (XSPA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
XpresSpa Group, Inc. (XSPA) delivered earnings and revenue surprises of 20% and 1.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ICLR vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ICLR vs. HQY: Which Stock Is the Better Value Option?
Has Elevance Health, Inc. (ELV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and HealthEquity (HQY) have performed compared to their sector so far this year.
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued strength in its Global Industrial segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances. However, the resurgence of COVID-19 infections is likely to have hurt sales growth.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
Why Is HealthEquity (HQY) Down 10% Since Last Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why HealthEquity (HQY) is Poised for a Turnaround After Losing 7.7% in 4 Weeks
by Zacks Equity Research
HealthEquity (HQY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why You Should Hold on to Accuray (ARAY) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.
Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine
by Zacks Equity Research
Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.
BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox
by Zacks Equity Research
BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.
BD (BDX) to Expand Base in Pharmacy Automation With New Buyout
by Zacks Equity Research
BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.
HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.
Here's Why You Should Hold on to Avanos (AVNS) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
HealthEquity (HQY) Q1 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -3.57% and 1.46%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Assure Holdings Corp. (IONM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -216.67% and 27.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -300% and 5.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Q1 Earnings Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.
HealthEquity (HQY) Q4 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?